AHR and cancer: Interestingly, immune checkpoint blockade (ICB) induces IDO1 and L-amino acid oxidase IL4I1, and IDO1 inhibitors do not block IL4I1,1 indicating that inhibition of novel AHR-mediator IL4I1 is an approach to cancer treatment.